DEXCOM INC — Director's Dealing 2023

Mar 14, 2023

SEC Form 4 — Statement of Changes in Beneficial Ownership

Issuer: DEXCOM INC (DXCM)
CIK: 0001093557
Period of Report: 2023-03-10

Reporting Person: Dolan Matthew Vincent (SVP Corporate Strategy-Develop)

Non-Derivative Transactions

Date	Security	Code	Shares	Price	A/D	Holdings After	Ownership
2023-03-10	Common Stock	D	1370	$111.399	Disposed	46935	Direct
2023-03-10	Common Stock	D	1650	$111.399	Disposed	45285	Direct
2023-03-10	Common Stock	D	2397	$111.399	Disposed	42888	Direct
2023-03-10	Common Stock	D	787	$111.399	Disposed	42101	Direct
2023-03-13	Common Stock	S	6229	$106.27	Disposed	35872	Direct

Footnotes

F1: Represents the number of shares required to be sold by the reporting person to cover tax withholding obligations in connection with the vesting of RSUs. This sale is mandated by the Issuer's election under its equity incentive plans to require the satisfaction of tax withholding obligations to be funded by a "sell to cover" transaction and does not represent a discretionary trade by the reporting person.

F2: Included in this number are 33,569 unvested restricted stock units, 21,769 of which were granted on March 8, 2023 and shall vest through March 8, 2026, 7,704 of which were granted on March 8, 2022 and shall vest through March 8, 2025, 4,096 of which were granted on March 8, 2021 and shall vest through March 8, 2024.

F3: On December 15, 2021, Mr. Dolan adopted a 10b5-1 Plan which was amended on December 6, 2022. This 10b5-1 Plan allows the orderly disposition of shares owned by Mr. Dolan. The shares set forth above were sold pursuant to the 10b5-1 Plan.